MARKET

TTIPF

TTIPF

Thiogenesis
OTCQX
0.440
0.000
0.00%
Closed 13:00 04/16 EDT
OPEN
0.430
PREV CLOSE
0.440
HIGH
0.440
LOW
0.430
VOLUME
9.50K
TURNOVER
4.17K
52 WEEK HIGH
0.586
52 WEEK LOW
0.370
MARKET CAP
20.25M
P/E (TTM)
-4.2553
1D
5D
1M
3M
1Y
5Y
1D
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Newsfile · 20h ago
Thiogenesis Therapeutics Announces Investigator-Initiated Study of TTI-0102 in Nephropathic Cystinosis
Reuters · 02/02 14:02
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
Newsfile · 02/02 14:00
Thiogenesis Therapeutics Reports Phase 2 MELAS Trial Shows Significant Fatigue Improvement with TTI-0102
Reuters · 01/26 07:14
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Newsfile · 01/23 14:00
Thiogenesis Therapeutics Reports Positive Phase 2 Results for TTI-0102 in MELAS Trial
Reuters · 01/13 14:02
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
Newsfile · 01/13 14:00
Thiogenesis Therapeutics Presents Clinical Updates at UMDF Bench-to-Bedside Webinar
Reuters · 01/05 14:02
More
About TTIPF
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Webull offers Thiogenesis Therapeutics Corp stock information, including OTCQX: TTIPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTIPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TTIPF stock methods without spending real money on the virtual paper trading platform.